Login / Signup

Cost-effectiveness analysis of the new oncological drug durvalumab in Italian patients with stage III non-small cell lung cancer.

Alessandra BujaGiulia PaselloMarco SchiavonGiuseppe De LucaMichele RiveraClaudia CozzolinoAnna De PoloManuela ScioniAlberto BortolamiVincenzo BaldoPierFranco Conte
Published in: Thoracic cancer (2022)
The study observed that durvalumab is a cost-effective treatment option for patients with unresectable stage III NSCLC.
Keyphrases
  • small cell lung cancer
  • rectal cancer
  • locally advanced
  • advanced non small cell lung cancer
  • prostate cancer
  • radical prostatectomy
  • radiation therapy
  • robot assisted
  • minimally invasive
  • replacement therapy